Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Elias Jabbour, Nicholas Short, Nitin Jain, Partow Kebriaei, Richard E Champlin, Issa F. Khouri, Elizabeth J Shpall, Patrice Nasnas, Aram Bidikian, Rebecca Garris, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 3155–3157.

https://doi.org/10.1182/blood-2022-171189

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4036–4038.

https://doi.org/10.1182/blood-2022-170069

Published: 2022

Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Blood (2022) 140 (Supplement 1): 9773–9775.

https://doi.org/10.1182/blood-2022-169213

Published: 2022

Journal Articles

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Courtney D. DiNardo, Nicholas Short, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Joby Joseph, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9771–9772.

https://doi.org/10.1182/blood-2022-170138

Published: 2022

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

Journal Articles

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Nitin Jain, Elias Jabbour, Ibrahim Aldoss, Marina Konopleva, Nicholas Short, Anthony S. Stein, Naveen Pemmaraju, Philip A. Thompson, Farhad Ravandi, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 521–522.

https://doi.org/10.1182/blood-2022-170730

Published: 2022

Journal Articles

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Emmanuel Almanza Huante, Elias Jabbour, Marina Konopleva, Cesar Nunez, Sergej Konoplev, Nicholas Short, Naveen Pemmaraju, Fatima Zahra Jelloul, Guilin Tang, Hagop Kantarjian, Nitin Jain

Blood (2022) 140 (Supplement 1): 3178–3180.

https://doi.org/10.1182/blood-2022-169370

Published: 2022

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Nicholas Short, Abhishek Maiti, Guillermo Montalban-Bravo, Naval Daver, Jitesh D. Kawedia, Kayleigh Bowie, Sherry A. Pierce, Farhad Ravandi, Marina Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 3344–3346.

https://doi.org/10.1182/blood-2022-169670

Published: 2022

Journal Articles

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Blood (2022) 140 (Supplement 1): 3324–3326.

https://doi.org/10.1182/blood-2022-158566

Published: 2022

Journal Articles

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

Guillermo Garcia-Manero, Vera Adema, Samuel Urrutia, Feiyang Ma, Hui Yang, Irene Ganan-Gomez, Gautam Borthakur, Koichi Takahashi, Nicholas Short, Ghayas C. Issa, Kelly S. Chien, Guillermo Montalban-Bravo, Joby Joseph, Simona Colla

Blood (2022) 140 (Supplement 1): 2078–2080.

https://doi.org/10.1182/blood-2022-167703

Published: 2022

Journal Articles

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Jayastu Senapati, Farhad Ravandi, Courtney D. DiNardo, Ghayas C. Issa, Koji Sasaki, Marina Konopleva, Naveen Pemmaraju, Kelly S. Chien, Maro Ohanian, Elias Jabbour, Abhishek Maiti, Edith Roy, Ricardo Delumpa, Juan Rivera, Christopher Loiselle, Glenda Banks, Hagop Kantarjian, Nicholas Short

Blood (2022) 140 (Supplement 1): 3880–3882.

https://doi.org/10.1182/blood-2022-170773

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Blood (2022) 140 (Supplement 1): 4872–4875.

https://doi.org/10.1182/blood-2022-162962

Published: 2022

Journal Articles

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies

Georgina Gener-Ricos, Koji Sasaki, Sanam Loghavi, Abhishek Maiti, Nicholas Short, Fadi Haddad, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Keyur P. Patel, Michael Andreeff, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 11830–11832.

https://doi.org/10.1182/blood-2022-167923

Published: 2022

Journal Articles

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 9078–9079.

https://doi.org/10.1182/blood-2022-167349

Published: 2022

Journal Articles

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2022) 140 (Supplement 1): 9050–9053.

https://doi.org/10.1182/blood-2022-171011

Published: 2022

Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Blood (2022) 140 (Supplement 1): 9041–9043.

https://doi.org/10.1182/blood-2022-168029

Published: 2022

Journal Articles

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Faustine Ong, Nicholas Short, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Musa Yilmaz, Yesid Alvarado, Kenneth Vaughan, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9029–9031.

https://doi.org/10.1182/blood-2022-159110

Published: 2022

Journal Articles

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Blood (2022) 140 (Supplement 1): 6064–6066.

https://doi.org/10.1182/blood-2022-170458

Published: 2022

NARROW

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial

A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only